Health systems that were early virtual care adopters have evolved their telehealth organizational strategies following the ...

With Pennsylvania's primary election less than three weeks away, WTAE Channel 4 is bringing voters a debate between the ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Legislation to protect health care staff from workplace violence passed the House Tuesday. It promises to enshrine OSHA ...

Clinical studies showed that Yesintek is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...